04/10/2021
MSD and Ridgeback Therapeutics announced that their investigational anti-viral medicine reduced the risk of hospitalisation and death by approximately 50% in non-hospitalised adult patients with mild-to-moderate COVID-19. The results come from MSD and Ridgeback Therapuetics’ Phase III MOVe-OUT trial, where the anti-viral pill, molnupiravir, was given as an oral medicine. While the medicine cut hospitalisations and deaths in around 50% of people, 7.3% of participants were either hospitalised or died through day 29 of the trial....
.(* )MSD and Ridgeback Rehab revealed that their investigational anti-viral medication minimized the danger of hospitalisation and death by roughly 50% in non-hospitalised adult clients with mild-to-moderate COVID-19. MSD and Ridgeback Rehab revealed that their investigational anti-viral medication....